Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORSE SEVEN: Safety of ONS-5010 in Vials vs PFS in Retinal Disorders
NCT05112861Phase 3Active, not recruiting
- Sponsor
- Outlook Therapeutics
- Start
- Nov 2021
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in age-related macular degeneration (AMD), diabetic macular edema (DME), branch retinal vein occlusion (BRVO), sponsored by Outlook Therapeutics. Started Nov 2021; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
age-related macular degeneration (AMD)diabetic macular edema (DME)branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT05112861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05112861.